[go: up one dir, main page]

MX2020003375A - Sales de inhibidores de macrofagos asociados a tumores (tam). - Google Patents

Sales de inhibidores de macrofagos asociados a tumores (tam).

Info

Publication number
MX2020003375A
MX2020003375A MX2020003375A MX2020003375A MX2020003375A MX 2020003375 A MX2020003375 A MX 2020003375A MX 2020003375 A MX2020003375 A MX 2020003375A MX 2020003375 A MX2020003375 A MX 2020003375A MX 2020003375 A MX2020003375 A MX 2020003375A
Authority
MX
Mexico
Prior art keywords
salts
derivatives useful
pyrrolotriazine derivatives
phenyl
inhibitors
Prior art date
Application number
MX2020003375A
Other languages
English (en)
Inventor
Yongzhong Wu
Yongchun Pan
Qun Li
Zhongjiang Jia
Jiacheng Zhou
Original Assignee
Incyte Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Corp filed Critical Incyte Corp
Publication of MX2020003375A publication Critical patent/MX2020003375A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/145—Maleic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente solicitud proporciona formas de sal de N-(4-(4-Amino-7-(1-isobutirilpiperidin-4-il)pirrolo[1,2-f][1,2,4] triazin-5-il)fenil)-1-isopropil-2,4-dioxo-3-(piridin-2-il)-1,2,3, 4-tetrahidropirimidina-5-carboxamida y N-(4-(4-Amino-7-(1-isobutir ilpiperidin-4-il)pirrolo[1,2-f][1,2,4]triazin-5-il)fenil)-1-isopr opil-2,4-dioxo-3-fenil-1,2,3,4-tetrahidropirimidina-5-carboxamida , que son útiles como inhibidores de cinasas TAM, así como procesos e intermedios relacionados con estas.
MX2020003375A 2017-09-27 2018-09-26 Sales de inhibidores de macrofagos asociados a tumores (tam). MX2020003375A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762564070P 2017-09-27 2017-09-27
US201862714196P 2018-08-03 2018-08-03
PCT/US2018/052925 WO2019067594A1 (en) 2017-09-27 2018-09-26 SALTS OF PYRROLOTRIAZINE DERIVATIVES USEFUL AS TAM INHIBITORS

Publications (1)

Publication Number Publication Date
MX2020003375A true MX2020003375A (es) 2020-08-03

Family

ID=63794769

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020003375A MX2020003375A (es) 2017-09-27 2018-09-26 Sales de inhibidores de macrofagos asociados a tumores (tam).

Country Status (34)

Country Link
US (4) US10633387B2 (es)
EP (2) EP3687996B1 (es)
JP (3) JP7504791B2 (es)
KR (1) KR102739325B1 (es)
CN (2) CN111386273B (es)
AU (2) AU2018342471B2 (es)
BR (1) BR112020006145A2 (es)
CA (1) CA3077308A1 (es)
CL (2) CL2020000791A1 (es)
CO (1) CO2020005009A2 (es)
CR (1) CR20200179A (es)
CY (1) CY1124952T1 (es)
DK (1) DK3687996T3 (es)
EC (1) ECSP20021655A (es)
ES (1) ES2904458T3 (es)
GE (1) GEP20227429B (es)
HU (1) HUE057190T2 (es)
IL (1) IL273579B1 (es)
JO (1) JOP20200081A1 (es)
LT (1) LT3687996T (es)
MA (1) MA50655B1 (es)
MD (1) MD3687996T2 (es)
MX (1) MX2020003375A (es)
PE (1) PE20210002A1 (es)
PH (1) PH12020550143A1 (es)
PL (1) PL3687996T3 (es)
PT (1) PT3687996T (es)
RS (1) RS62872B1 (es)
SA (1) SA520411638B1 (es)
SG (1) SG11202002821UA (es)
SI (1) SI3687996T1 (es)
SM (1) SMT202200011T1 (es)
TW (1) TWI821200B (es)
WO (1) WO2019067594A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10053465B2 (en) 2015-08-26 2018-08-21 Incyte Corporation Pyrrolopyrimidine derivatives as TAM inhibitors
JP7071917B2 (ja) 2015-12-09 2022-05-19 カデント セラピューティクス，インコーポレーテッド ヘテロ芳香族ｎｍｄａ受容体モジュレーターおよびその使用
MD3436461T2 (ro) 2016-03-28 2024-05-31 Incyte Corp Compuși pirolotriazină ca inhibitori TAM
JP7332472B2 (ja) 2016-12-22 2023-08-23 ノバルティス アーゲー Ｎｍｄａ受容体モジュレーターおよびその使用
LT3687996T (lt) * 2017-09-27 2022-01-10 Incyte Corporation Pirolotriazino darinių druskos, naudingos kaip tam inhibitoriai
SG11202013163TA (en) 2018-06-29 2021-01-28 Incyte Corp Formulations of an axl/mer inhibitor
MA53351B1 (fr) 2018-08-03 2023-08-31 Novartis Ag Modulateurs des récepteurs nmda hétéroaromatiques et leurs utilisations
CR20250050A (es) 2018-09-05 2025-03-19 Incyte Corp Formas cristalinas de un inhibidor de fosfoinositida 3–quinasa (pi3k) (divisional 2021-0165)
WO2021178779A1 (en) * 2020-03-06 2021-09-10 Incyte Corporation Combination therapy comprising axl/mer and pd-1/pd-l1 inhibitors
US20230279024A1 (en) * 2020-07-10 2023-09-07 Beijing Findcure Biosciences, Ltd. Triazine compound and composition and use thereof
CN115028648B (zh) * 2021-03-03 2024-08-30 武汉誉祥医药科技有限公司 三并环化合物及其药物组合物和应用
WO2023286719A1 (ja) * 2021-07-13 2023-01-19 日本曹達株式会社 ウラシル化合物の製造方法

Family Cites Families (137)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5156840A (en) 1982-03-09 1992-10-20 Cytogen Corporation Amine-containing porphyrin derivatives
US5057313A (en) 1986-02-25 1991-10-15 The Center For Molecular Medicine And Immunology Diagnostic and therapeutic antibody conjugates
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2, Inc., Danville, Calif. Geänderte antikörper.
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
JPH0395163A (ja) 1989-09-08 1991-04-19 Daicel Chem Ind Ltd ２．２．４．４．６―ペンタメチル―２．３．４．５―テトラヒドロピリミジンの製造法
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
LU91067I2 (fr) 1991-06-14 2004-04-02 Genentech Inc Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines
AU3178993A (en) 1991-11-25 1993-06-28 Enzon, Inc. Multivalent antigen-binding proteins
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
JP4436457B2 (ja) 1995-08-18 2010-03-24 モルフォシス アイピー ゲーエムベーハー 蛋白質／（ポリ）ペプチドライブラリー
US20020077461A1 (en) 1996-04-24 2002-06-20 Soren Bjorn Pharmaceutical formulation
WO2001019828A2 (en) 1999-09-17 2001-03-22 Basf Aktiengesellschaft Kinase inhibitors as therapeutic agents
KR100786927B1 (ko) 2000-06-28 2007-12-17 스미스클라인비이참피이엘시이 습식 분쇄방법
CA2442849A1 (en) 2001-04-06 2002-10-17 Wyeth Antineoplastic combinations such as rapamycin together with gemcitabine or fluorouracil
GB0221697D0 (en) 2002-09-18 2002-10-30 Unilever Plc Novel compouds and their uses
AU2003272175A1 (en) 2002-10-21 2004-05-04 Aprea Ab Reactivation of wild type p53 in human tumour cells by a low molecular weight compound
AU2004204494B2 (en) 2003-01-09 2011-09-29 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
AU2004205631A1 (en) 2003-01-16 2004-08-05 Genentech, Inc. Synthetic antibody phage libraries
US20050008625A1 (en) 2003-02-13 2005-01-13 Kalobios, Inc. Antibody affinity engineering by serial epitope-guided complementarity replacement
ATE399538T1 (de) 2003-03-26 2008-07-15 Egalet As Matrixzubereitungen für die kontrollierte darreichung von arzneistoffen
WO2005003175A2 (en) 2003-06-13 2005-01-13 Biogen Idec Ma Inc. Aglycosyl anti-cd154 (cd40 ligand) antibodies and uses thereof
NZ545776A (en) 2003-08-22 2009-05-31 Biogen Idec Inc Improved antibodies having altered effector function and methods for making the same
WO2005025515A2 (en) 2003-09-12 2005-03-24 California Institute Of Technology Proteasome pathway inhibitors and related methods
CN1960993A (zh) 2004-04-02 2007-05-09 Osi制药公司 6,6－双环取代的杂双环蛋白激酶抑制剂
UY28931A1 (es) 2004-06-03 2005-12-30 Bayer Pharmaceuticals Corp Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis
AR053090A1 (es) 2004-07-20 2007-04-25 Osi Pharm Inc Imidazotriazinas como inhibidores de proteina quinasas y su uso para la preparacion de medicamentos
UY29177A1 (es) 2004-10-25 2006-05-31 Astex Therapeutics Ltd Derivados sustituidos de purina, purinona y deazapurina, composiciones que los contienen métodos para su preparación y sus usos
WO2006056399A2 (en) 2004-11-24 2006-06-01 Novartis Ag Combinations of jak inhibitors and at least one of bcr-abl, flt-3, fak or raf kinase inhibitors
BRPI0618622A2 (pt) * 2005-11-17 2011-09-06 Osi Pharm Inc composto, composição, e, uso de um composto
BRPI0619146A2 (pt) 2005-12-02 2011-09-13 Bayer Pharmaceuticals Corp derivados de 4-amino-pirroltriazina substituìda úteis no tratamento de disordens e doenças hiperproliferativas associadas com angiogênesis
PE20070855A1 (es) * 2005-12-02 2007-10-14 Bayer Pharmaceuticals Corp Derivados de 4-amino-pirrolotriazina sustituida como inhibidores de quinasas
WO2007070514A1 (en) 2005-12-13 2007-06-21 Incyte Corporation Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
WO2007070872A1 (en) 2005-12-15 2007-06-21 Rigel Pharmaceuticals, Inc. Kinase inhibitors and their uses
RU2441006C2 (ru) 2006-04-12 2012-01-27 Вертекс Фармасьютикалз Инкорпорейтед 4, 5-ДИГИДРО-[1, 2, 4]ТРИАЗОЛО[4, 3-F]ПТЕРИДИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ ПРОТЕИНКИНАЗЫ Plk1 ДЛЯ ЛЕЧЕНИЯ ПРОЛИФЕРАТИВНЫХ ЗАБОЛЕВАНИЙ
DK2010528T3 (en) 2006-04-19 2018-01-15 Novartis Ag 6-O-Substituted Benzoxazole and Benzothiazole Compounds and Methods for Inhibiting CSF-1R Signaling
US20090253718A1 (en) 2006-04-25 2009-10-08 Astex Therapeutics Limited Pharmaceutical Compounds
US20090306103A1 (en) 2006-05-19 2009-12-10 Stephen Boyer Pyridonecarboxamide derivatives useful in treating hyper-proliferative and angiogenesis disorders
WO2008045978A1 (en) 2006-10-10 2008-04-17 Rigel Pharmaceuticals, Inc. Pinane-substituted pyrimidinediamine derivatives useful as axl inhibitors
CN101641093B (zh) 2006-11-22 2013-05-29 因塞特公司 作为激酶抑制剂的咪唑并三嗪和咪唑并嘧啶
US8129387B2 (en) 2006-12-14 2012-03-06 Vertex Pharmaceuticals Incorporated Substituted 5,6-dihydroimidazo[1,5-F]pteridines useful as protein kinase inhibitors
EP2484679B1 (en) 2006-12-29 2016-09-28 Rigel Pharmaceuticals, Inc. N3-heteroaryl substituted triazoles and n5-heteroaryl substitued triazoles useful as axl inhibitors
PT2078010E (pt) 2006-12-29 2014-05-07 Rigel Pharmaceuticals Inc Triazoles substituídos com heteroarilos policíclicos úteis como inibidores de axl
EP2114954B1 (en) 2006-12-29 2013-02-13 Rigel Pharmaceuticals, Inc. Bicyclic aryl and bicyclic heteroaryl substituted triazoles useful as axl inhibitors
US8168415B2 (en) 2007-02-07 2012-05-01 The Regents Of The University Of Colorado Axl fusion proteins as Axl tyrosine kinase inhibitors
US20100086592A1 (en) 2007-03-29 2010-04-08 Panacea Biotec Limited. Modified dosage forms of tacrolimus
ES2395137T3 (es) 2007-06-12 2013-02-08 Concert Pharmaceuticals, Inc. Derivados de azapéptidos como inhibidores de la proteasa VIH
CA2695753A1 (en) 2007-08-15 2009-02-19 Vertex Pharmaceuticals Incorporated Compounds useful as protein kinases inhibitors
GB0719803D0 (en) 2007-10-10 2007-11-21 Cancer Rec Tech Ltd Therapeutic compounds and their use
CA2703653A1 (en) 2007-10-25 2009-04-30 Astrazeneca Ab Pyridine and pyrazine derivatives -083
ES2424259T3 (es) 2007-10-26 2013-09-30 Rigel Pharmaceuticals, Inc. Triazoles sustituidos con arilo policíclico y heteroarilo policíclico, útiles como agentes inhibidores del Axl
EA201001030A1 (ru) 2007-12-19 2011-02-28 Амген Инк. Конденсированные соединения пиридина, пиримидина и триазина в качестве ингибиторов клеточного цикла
AR070127A1 (es) 2008-01-11 2010-03-17 Novartis Ag Pirrolo - pirimidinas y pirrolo -piridinas
US9206130B2 (en) 2008-04-16 2015-12-08 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Quinoline derivatives as AXL kinase inhibitors
TWI539953B (zh) 2008-04-28 2016-07-01 瑞波若斯治療學公司 用於治療乳癌之組成物和方法
CN102076690A (zh) 2008-06-23 2011-05-25 维泰克斯制药公司 蛋白激酶抑制剂
CA2730231C (en) 2008-07-09 2016-10-18 Rigel Pharmaceuticals, Inc. Polycyclic heteroaryl substituted triazoles useful as axl inhibitors
PL2328888T3 (pl) 2008-07-09 2013-04-30 Rigel Pharmaceuticals Inc Triazole podstawione mostkowanym bicyklicznym heteroarylem użyteczne jako inhibitory AXL
US20120230991A1 (en) 2008-07-29 2012-09-13 Douglas Kim Graham Methods and compounds for enhancing anti-cancer therapy
EP2158913A1 (en) 2008-08-25 2010-03-03 Ratiopharm GmbH Pharmaceutical composition comprising N-[3-chhloro-4-[(3-fluorophenyl)methoxy]phenyl]6-(5[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furyl]-4-quinazolinamine
WO2010025073A1 (en) 2008-08-28 2010-03-04 Takeda Pharmaceutical Company Limited Dihydroimidazo [ 1, 5-f] pteridines as polo-like kinase inhibitors
AR074830A1 (es) 2008-12-19 2011-02-16 Cephalon Inc Pirrolotriazinas como inhibidores de alk y jak2
WO2010090764A1 (en) 2009-02-09 2010-08-12 Supergen, Inc. Pyrrolopyrimidinyl axl kinase inhibitors
US8765754B2 (en) 2009-04-29 2014-07-01 Locus Pharmaceuticals, Inc. Pyrrolotriazine compounds
WO2011139273A1 (en) 2010-05-05 2011-11-10 Vertex Pharmaceuticals Incorporated 4 substituted pyrazolopyrimidines useful as pkc-theta inhibitors
NZ596479A (en) 2009-05-22 2014-01-31 Incyte Corp N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
MX2011013816A (es) 2009-06-29 2012-04-11 Incyte Corp Pirimidinonas como inhibidores de pi3k.
TW201113285A (en) 2009-09-01 2011-04-16 Incyte Corp Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
BR112012006639A2 (pt) 2009-09-25 2015-09-08 Vertex Pharma métodos para preparar derivados de pirimidina úteis como inibidores de protéina quinase
EP2311809A1 (en) 2009-10-16 2011-04-20 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Quinolinyloxyphenylsulfonamides
US8604217B2 (en) 2009-11-12 2013-12-10 Selvita S.A. Compound, a process for its preparation, a pharmaceutical composition, use of a compound, a method for modulating or regulating serine/threonine kinases and a serine/threonine kinases modulating agent
AR079529A1 (es) 2009-12-18 2012-02-01 Incyte Corp Derivados arilo y heteroarilo sustituidos y fundidos como inhibidores de la pi3k
AU2011224484A1 (en) 2010-03-10 2012-09-27 Incyte Holdings Corporation Piperidin-4-yl azetidine derivatives as JAK1 inhibitors
EP2552922A1 (en) 2010-03-31 2013-02-06 Bristol-Myers Squibb Company Substituted pyrrolotriazines as protein kinase inhibitors
US9290499B2 (en) 2010-05-19 2016-03-22 The University Of North Carolina At Chapel Hill Pyrazolopyrimidine compounds for the treatment of cancer
EP2423208A1 (en) 2010-08-28 2012-02-29 Lead Discovery Center GmbH Pharmaceutically active compounds as Axl inhibitors
BR112013008526A2 (pt) 2010-10-08 2016-07-12 Elan Pharm Inc inibidores de quinase do tipo polo
ITRM20100537A1 (it) 2010-10-12 2012-04-12 Consiglio Nazionale Ricerche Aptamero inibitore del recettore tirosina chinasi axl per uso in terapia
PE20140146A1 (es) 2010-11-19 2014-02-06 Incyte Corp Derivados de pirrolopiridina y pirrolopirimidina sustituidos con ciclobutilo como inhibidores de jak
CA2818545C (en) 2010-11-19 2019-04-16 Incyte Corporation Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as jak inhibitors
ES2764848T3 (es) 2010-12-20 2020-06-04 Incyte Holdings Corp N-(1-(fenilo sustituido)etilo)-9H-purina-6-aminas como inhibidores de PI3K
US9133162B2 (en) 2011-02-28 2015-09-15 Sunshine Lake Pharma Co., Ltd. Substituted quinoline compounds and methods of use
AU2012230896B9 (en) 2011-03-23 2015-06-18 Amgen Inc. Fused tricyclic dual inhibitors of CDK 4/6 and FLT3
ES2759615T3 (es) 2011-04-01 2020-05-11 Univ Utah Res Found Análogos de N-fenilpirimidina-2-amina sustituidos como inhibidores de la quinasa AXL
AR086913A1 (es) 2011-06-14 2014-01-29 Novartis Ag 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]-amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluoro-metil)-fenil]-benzamida amorfa, forma de dosificacion que la contiene y metodo para prepararlas
WO2012177606A1 (en) 2011-06-20 2012-12-27 Incyte Corporation Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors
US9040691B2 (en) 2011-07-01 2015-05-26 Bayer Intellectual Property Gmbh Hydroxymethylaryl-substituted pyrrolotriazines as ALK1 inhibitors
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
KR20230038593A (ko) 2011-09-02 2023-03-20 인사이트 홀딩스 코포레이션 Ｐｉ３ｋ 억제제로서 헤테로시클릴아민
PL2758052T3 (pl) 2011-09-18 2018-10-31 Euro-Celtique S.A. Kompozycja farmaceutyczna zawierająca inhibitor HDAC i cyklopolisacharyd
CN102408411B (zh) 2011-09-19 2014-10-22 北京康辰药业股份有限公司 一种含喹啉基的羟肟酸类化合物及其制备方法、以及含有该化合物的药物组合物及其应用
CN103958510B (zh) 2011-10-03 2016-10-19 北卡罗来纳大学教堂山分校 用于治疗癌症的吡咯并嘧啶化合物
ES2614824T3 (es) 2011-11-14 2017-06-02 Ignyta, Inc. Derivados de uracil como inhibidores de la quinasa axl y c-met
PL2785700T3 (pl) 2011-11-29 2016-09-30 Środki odwracające działanie przeciwzakrzepowe
US8993756B2 (en) 2011-12-06 2015-03-31 Merck Sharp & Dohme Corp. Pyrrolopyrimidines as janus kinase inhibitors
UY34484A (es) 2011-12-15 2013-07-31 Bayer Ip Gmbh Benzotienilo-pirrolotriazinas disustituidas y sus usos
MY165215A (en) 2012-01-31 2018-03-09 Daiichi Sankyo Co Ltd Pyridone derivatives
JP6082033B2 (ja) 2012-02-23 2017-02-15 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ 置換ベンゾチエニル−ピロロトリアジンおよびその使用
WO2013162061A1 (ja) 2012-04-26 2013-10-31 第一三共株式会社 二環性ピリミジン化合物
WO2013173720A1 (en) 2012-05-18 2013-11-21 Incyte Corporation Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
JP6318156B2 (ja) 2012-09-06 2018-04-25 プレキシコン インコーポレーテッドＰｌｅｘｘｉｋｏｎ Ｉｎｃ． キナーゼをモジュレートするための化合物および方法、ならびにその指標
BR112015006828A8 (pt) 2012-09-26 2019-09-17 Univ California composto, ou um sal farmaceuticamente aceitável do mesmo; composição farmacêutica; uso do composto; e método para modular a atividade de uma proteína ire1
WO2014062774A1 (en) 2012-10-17 2014-04-24 The University Of North Carolina At Chapel Hill Pyrazolopyrimidine compounds for the treatment of cancer
JP6359546B2 (ja) 2012-11-01 2018-07-18 インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ Ｊａｋ阻害薬としての三環式縮合チオフェン誘導体
US9925193B2 (en) 2012-11-20 2018-03-27 Proqinase Gmbh Thioether derivatives as protein kinase inhibitors
US20150353542A1 (en) 2013-01-14 2015-12-10 Amgen Inc. Methods of using cell-cycle inhibitors to modulate one or more properties of a cell culture
TW201522337A (zh) 2013-03-12 2015-06-16 Arqule Inc 經取代之三環吡唑並－嘧啶化合物類
TWI649308B (zh) 2013-07-24 2019-02-01 小野藥品工業股份有限公司 喹啉衍生物
US9586967B2 (en) 2013-11-08 2017-03-07 Ono Pharmaceutical Co., Ltd. Pyrrolo pyrimidine derivative
WO2015081783A1 (zh) 2013-12-06 2015-06-11 江苏奥赛康药业股份有限公司 吡咯并[2,1-f][1,2,4]三嗪类衍生物及其制备方法和用途
AP2016009297A0 (en) 2014-02-03 2016-06-30 Cadila Healthcare Ltd Novel heterocyclic compounds
GB201420285D0 (en) 2014-11-14 2014-12-31 Bergenbio As Process
EP3233829B1 (en) 2014-12-18 2019-08-14 Pfizer Inc Pyrimidine and triazine derivatives and their use as axl inhibitors
WO2016183071A1 (en) * 2015-05-11 2016-11-17 Incyte Corporation Hetero-tricyclic compounds and their use for the treatment of cancer
PE20181151A1 (es) 2015-07-30 2018-07-17 Macrogenics Inc Moleculas de union a pd-1 y metodos de uso de las mismas
US9708333B2 (en) 2015-08-12 2017-07-18 Incyte Corporation Fused bicyclic 1,2,4-triazine compounds as TAM inhibitors
US10053465B2 (en) 2015-08-26 2018-08-21 Incyte Corporation Pyrrolopyrimidine derivatives as TAM inhibitors
WO2017062797A1 (en) 2015-10-07 2017-04-13 The University Of North Carolina At Chapel Hill The methods for treatment of tumors
AU2016337957B2 (en) 2015-10-13 2018-11-08 Nihon Nohyaku Co., Ltd. Oxime group-containing condensed heterocyclic compound or salt thereof, agricultural and horticultural insecticide comprising the compound, and method for using the insecticide
JP6921818B2 (ja) 2015-11-14 2021-08-18 サンシャイン・レイク・ファーマ・カンパニー・リミテッドＳｕｎｓｈｉｎｅ Ｌａｋｅ Ｐｈａｒｍａ Ｃｏ．，Ｌｔｄ． 置換キノリン化合物の結晶形およびその医薬組成物
US9695150B2 (en) 2015-11-14 2017-07-04 Calitor Sciences, Llc Crystalline form of a substituted quinoline compound and pharmaceutical compositions thereof
MD3436461T2 (ro) * 2016-03-28 2024-05-31 Incyte Corp Compuși pirolotriazină ca inhibitori TAM
TWI833686B (zh) 2016-04-22 2024-03-01 美商英塞特公司 Lsd1 抑制劑之調配物
WO2017223414A1 (en) * 2016-06-24 2017-12-28 Incyte Corporation HETEROCYCLIC COMPOUNDS AS PI3K-γ INHIBITORS
KR102556825B1 (ko) 2016-07-15 2023-07-17 아이오니스 파마수티컬즈, 인코포레이티드 Smn2 조정을 위한 조성물 및 방법
JOP20170153A1 (ar) 2016-07-15 2019-01-30 Lilly Co Eli نظائر urocortin-2 جديدة معدلة بحمض دهني لعلاج داء السكري وأمراض الكلى المزمنة
JOP20190257A1 (ar) 2017-04-28 2019-10-28 Novartis Ag مركبات أريل غير متجانسة ثنائية الحلقة مندمجة 6-6 واستخدامها كمثبطات lats
LT3687996T (lt) 2017-09-27 2022-01-10 Incyte Corporation Pirolotriazino darinių druskos, naudingos kaip tam inhibitoriai
SG11202013163TA (en) 2018-06-29 2021-01-28 Incyte Corp Formulations of an axl/mer inhibitor
WO2021178779A1 (en) 2020-03-06 2021-09-10 Incyte Corporation Combination therapy comprising axl/mer and pd-1/pd-l1 inhibitors

Also Published As

Publication number Publication date
MA50655B1 (fr) 2021-11-30
AU2018342471A1 (en) 2020-04-23
JP7504791B2 (ja) 2024-06-24
PH12020550143A1 (en) 2020-12-07
BR112020006145A2 (pt) 2020-10-20
US20200347065A1 (en) 2020-11-05
CA3077308A1 (en) 2019-04-04
JP7639195B2 (ja) 2025-03-04
AU2018342471B2 (en) 2023-08-24
KR20200088308A (ko) 2020-07-22
MA50655A (fr) 2021-06-02
IL273579B1 (en) 2025-06-01
US20190112313A1 (en) 2019-04-18
AU2023270198A1 (en) 2023-12-14
DK3687996T3 (da) 2022-01-10
MD3687996T2 (ro) 2022-04-30
SG11202002821UA (en) 2020-04-29
CN118930549A (zh) 2024-11-12
CY1124952T1 (el) 2023-01-05
WO2019067594A1 (en) 2019-04-04
SI3687996T1 (sl) 2022-04-29
CL2020000791A1 (es) 2020-09-25
LT3687996T (lt) 2022-01-10
CR20200179A (es) 2020-11-02
CO2020005009A2 (es) 2020-05-29
JP2025093936A (ja) 2025-06-24
CL2022001014A1 (es) 2022-11-18
EP3988552A1 (en) 2022-04-27
SA520411638B1 (ar) 2024-03-28
HUE057190T2 (hu) 2022-04-28
EP3687996B1 (en) 2021-11-03
ES2904458T3 (es) 2022-04-05
KR102739325B1 (ko) 2024-12-09
US10633387B2 (en) 2020-04-28
PL3687996T3 (pl) 2022-02-21
CN111386273B (zh) 2024-06-14
IL273579A (en) 2020-05-31
US11104682B2 (en) 2021-08-31
JOP20200081A1 (ar) 2020-04-30
US20220227770A1 (en) 2022-07-21
US12187730B2 (en) 2025-01-07
US20250188086A1 (en) 2025-06-12
SMT202200011T1 (it) 2022-03-21
EP3687996A1 (en) 2020-08-05
PT3687996T (pt) 2022-01-21
ECSP20021655A (es) 2020-07-31
TWI821200B (zh) 2023-11-11
JP2024059647A (ja) 2024-05-01
RS62872B1 (sr) 2022-02-28
CN111386273A (zh) 2020-07-07
GEP20227429B (en) 2022-10-25
TW201920186A (zh) 2019-06-01
PE20210002A1 (es) 2021-01-05
JP2020535168A (ja) 2020-12-03

Similar Documents

Publication Publication Date Title
MX2020003375A (es) Sales de inhibidores de macrofagos asociados a tumores (tam).
WO2017108723A3 (en) PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS
NZ627454A (en) 2-amino, 6-phenyl substituted pyrido [2,3-d] pyrimidine derivatives useful as raf kinase inhibitors
EP3797109A4 (en) HETEROCYCLIC COMPOUNDS USED AS KINASE INHIBITORS, COMPOSITIONS COMPRISING THE HETEROCYCLIC COMPOUND, AND METHODS OF USE THEREOF
EA201591255A1 (ru) ПРОИЗВОДНЫЕ ПИРРОЛО[2,3-d]ПИРИМИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ ЯНУС-РОДСТВЕННЫХ КИНАЗ (JAK)
EP3672973A4 (en) HETEROCYCLIC COMPOUNDS USED AS KINASE INHIBITORS, COMPOSITIONS INCLUDING THE HETEROCYCLIC COMPOUND, AND METHODS OF USE THEREOF
ZA202101788B (en) Aminopyrimidine/pyrazine derivatives as ctps1 inhibitors
CY1114539T1 (el) Η χρησιμοτητα των ιμιδαζοπυριδαζινοκαρβονιτριλιων ως αναστολεων κινασων
TN2018000087A1 (en) New pyrrolo[2,3-d]pyrimidine derivatives as dual dyrk1/clk1 inhibitors
NO20075987L (no) Bisykliske derviater som p38-kinaseinhibitorer
MX2012009074A (es) Compuestos de urea pirrolo [2, 3-d] pirimidina como inhibidores de janus quinasa.
PH12019501022A1 (en) Pyrazolopyrimidine compounds and methods of use thereof
CY1122423T1 (el) Παραγωγα πυριμιδινης χρησιμα ως εκλεκτικοι αναστολεις jak3 kai/ή jak1
CL2021002656A1 (es) Compuestos de pirrolotriazina, inhibidores selectivos de proteínas quinasas kit y pdgfralfa; composición y uso.
WO2020089687A3 (en) Fused heterocyclic benzodiazepine derivatives and uses thereof
PE20170936A1 (es) Compuestos novedosos de imidazopiridazina y su uso
WO2019229536A3 (en) Novel benzodiazepine derivatives and uses thereof
IL276160A (en) A salt of the compound pyrazolo[5,1-]pyrimidine and its crystals
PH12020551465A1 (en) Solid forms of substituted 5,6-dihydro-6-phenylbenzo[f]isoquinolin-2-amine compounds
MX2015013365A (es) Derivados de urea y su uso como inhibidores de proteina de union de acidos grasos (puag).
MX2015013374A (es) Derivados de urea y su uso como inhibidores de proteina de uniuon a acidos grasos (puag).
EA202090836A1 (ru) Соли производных пирролотриазинов, пригодных для использования в качестве ингибиторов tam
HK40046602B (en) Heterocyclic compounds as kinase inhibitors, compositions comprising the heterocyclic compound, and methods of use thereof
AU2017903306A0 (en) DERIVATIVES OF 4-(IMIDAZO[1,2-b]PYRIDAZIN-3-YL) PYRIMIDIN-2-AMINE AND THEIR USE AS INHIBITORS OF PROTEIN KINASES
CY1115106T1 (el) Ενωσεις πυρρολο[2,3-d]πυριμιδινης